CGTLive®’s Weekly Rewind – October 4, 2024
Review top news and interview highlights from the week ending October 4, 2024.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Cilta-cel Boosts Overall Survival in New Early Line Multiple Myeloma Data
The data, from the CARTITUDE-4 clinical trial, compared outcomes to patients treated with standard of care options.
2. Arun Upadhyay, PhD, on Results from IRD Gene Therapy OCU400’s Phase 1/2 Trial
The chief scientific officer and head of research, development, and Medical at Ocugen, also discussed future plans for the gene therapy, which is now in a phase 3 study.
3. Anixa Biosciences Seeks Protocol Change to Enable Repeat Dosing in Trial for Ovarian Cancer CER-T
Anixa noted that it had previously obtained clearance of a single-patient investigational new drug application to redose a patient in the trial.
4. CRISPR-Mediated In Vivo Epigenomic Activation
Daniel Hart, PhD, the senior director and head of technology development at Epic Bio, discussed potential applications of the new technology.
5. Myrtelle’s Canavan Disease Gene Therapy rAAV-Olig001-ASPA Decreases N-Acetylaspartate Levels in Phase 1/2 Study
CSF analyses from 7 patients treated in the study showed reductions of more than 80% in NAA levels from baseline.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
